Duchenne muscular dystrophy trials in Germany

In Germany 10 Also abroad 87

10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
Where
Essen, Heidelberg, München
Age
7 years to 16 years
People
70 worldwide
Run by
Avidity Biosciences, Inc.
See details and how to joinNCT07587242
Phase 3Taking people
Study in which all the patients take the same investigational drug with the aim of evaluate the long-term safety, tolerability, and efficacy of GIVINOSTAT in all the patients affected with Duchenne Muscolar Dystrophy who have been already treated in one of the GIVINOSTAT studies in the past
Where
Berlin, Essen, Freiburg im Breisgau, Hamburg, Munich
Age
Up to 64 years
People
207 worldwide
Run by
Italfarmaco S.p.A.
See details and how to join2023-504520-26-00 · EU 2023-504520-26-00
No phaseTaking people
Registry for Duchenne and Becker Muscular Dystrophy
Where
Berlin, Bochum, Bonn, Bremen, Dresden, Erlangen, Essen, Freiburg im Breisgau, Giessen, Göttingen, Greifswald, Hamburg, Hanover, Heidelberg, Homburg, Jena, Kassel, Leipzig, München, Münster, Stuttgart, Tübingen, Ulm
People
1,500 worldwide
Run by
Dr. Andreas Ziegler
See details and how to joinNCT07402122
Phase 3Taking people
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Where
Essen, Freiburg im Breisgau, Munich
Age
7 years to 11 years
People
80 worldwide
Run by
Solid Biosciences Inc.
See details and how to joinNCT07160634 · EU 2025-522949-22-00
Phase 2Enrolling by invitation
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Where
Munich
People
260 worldwide
Run by
Edgewise Therapeutics, Inc.
See details and how to joinNCT06066580
Phase 1/2Taking people
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
Where
Essen, Goettingen
Age
4 years to 20 years
People
24 worldwide
Run by
Entrada Therapeutics, Inc.
See details and how to joinNCT07037862 · EU 2024-517584-23-00
Phase 3Taking people
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
Where
Berlin, Essen, Freiburg im Breisgau, Hamburg
Age
9 years to 17 years
People
138 worldwide
Run by
Italfarmaco
See details and how to joinNCT05933057 · EU 2023-503521-19-00
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
Where
Essen, Heidelberg, Munich
Age
Up to 17 years
People
42 worldwide
Run by
Avidity Biosciences Inc.
See details and how to join2025-523087-20-00 · EU 2025-523087-20-00
Phase 3Enrolling by invitation
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
Where
Essen
Age
Up to 64 years
People
400 worldwide
Run by
Sarepta Therapeutics, Inc.
See details and how to joinNCT05967351 · EU 2023-505043-39-00
Phase 2/3Taking people
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Where
Essen, Hamburg, München
Age
7 years and over
People
206 worldwide
Run by
Italfarmaco
See details and how to joinNCT03373968